Home/Pipeline/Oncology Digital Biomarkers

Oncology Digital Biomarkers

Lung Cancer

DevelopmentActive

Key Facts

Indication

Lung Cancer

Phase

Development

Status

Active

Company

Imvaria

About Imvaria

Imvaria, founded in 2019 by physician-engineers from Google and Stanford, is a private, commercial-stage diagnostics company based in Berkeley, California. It has developed Fibresolve, the first FDA-authorized AI diagnostic tool for IPF/ILD, and is expanding its platform to other areas like lung cancer through a strategic collaboration with Mayo Clinic. The company operates a Digital Biomarker Lab, leveraging machine learning to create software-only biomarkers from complex clinical data, positioning it at the intersection of AI, radiology, and precision diagnostics.

View full company profile

Therapeutic Areas

Pulmonology Oncology

Other Lung Cancer Drugs

Drug	Company	Phase	Status
OncoStrong™	Lamark Biotech	Preclinical	Active
15dPMJ2	Claradele Pharmaceuticals	Research	Exploratory (Pathway Implied)
SUPLEXA	Alloplex Biotherapeutics	Phase 1	Completed
Aerosolized Platinum Nanoparticles	HylaPharm	Pre-clinical	Active
ENV105	Kairos Pharma	Phase 1	Active
AI for Lung Cancer	Invenio Imaging	Research	Active
Liposome Program	NanoTech Pharma	Preclinical/Phase 1/2	Active
Dendritic Cell Vaccine	MegaNano BioTech	Pre-clinical	Active
AI Biomarkers for Lung Cancer	BioAI Health	Unknown	Active
PRDM2 Target	ARIZ Precision Medicine	Preclinical	Active
ZEN-3694	Zenith Epigenetics	Proof-of-Concept	Active
TEC-001 + Keytruda	Teclison	Phase 2	Active